Comparison of cholesterol-lowering efficacy and anti-atherogenic properties of hydrogenated versus non-hydrogenated (Phytrol) tall oil-derived phytosterols in apo E-deficient mice.

The cholesterol-lowering and anti-atherogenic effects of non-hydrogenated (FCP-3P1 containing 69% beta-sitosterol, 16% sitostanol, and 13% campesterol) and hydrogenated (FCP-3P2 containing 77% sitostanol, 11% campestanol, and 8% beta-sitosterol) Phytrol trade mark have been compared in apo E-deficient mice. After consumption of 0.2% (w/w) cholesterol-enriched diet, the elevated plasma cholesterol levels observed in controls was significantly reduced by the addition of either 0.

Influence of phytostanol phosphoryl ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels, and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats.

The purpose of this investigation was to determine the effects of Phytostanol Phosphoryl Ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels, body weight, and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats. A group of 12 age-matched male obese (n = 6) and lean (n = 6) Zucker rats were administered 250 mg/kg twice a day (as 2% FM-VP4 in drinking water) for 30 consecutive days. Fasted blood samples prior to and following treatment were taken from all rats for glucose, lipid, insulin, and leptin determination.